Ayahuasca for Schizophrenia

3 papers and 0 clinical trials exploring ayahuasca as a treatment for schizophrenia.

Compoundclassic psychedelic

Ayahuasca

Ayahuasca is a botanical decoction combining DMT with MAO-inhibiting harmala alkaloids, producing intense psychedelic effects lasting 3-6 hours. Clinical trials show rapid, large antidepressant effects from a single dose, with a favourable safety profile in controlled settings.

Full Ayahuasca profile

IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

3 papers

Open Accessmeta

Default Mode Network Modulation by Psychedelics: A Systematic Review

This systematic review shows that classical psychedelics (LSD, psilocybin, ayahuasca) consistently cause acute disruption of resting-state connectivity within the Default Mode Network and increase cross-network functional connectivity, but it remains unclear how central DMN modulation is to their therapeutic effects. The article synthesises existing evidence and highlights gaps to guide future mechanistic research.

Published: October 22, 2022
Journal: International Journal of Neuropsychopharmacology
Authors: Castle, D., Downey, L., Galvão-Coelho, N. L., Gattuso, J. J., Hoyer, D., Jacobson, L. H., Lawrence, A. J., Nutt, D. J., Pagni, B. A., Perkins, D., Rossell, S. L., Ruffell, S. G. D., Sarris, J., Timmermann, C.

Open Accessmeta

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

This systematic review of case reports found that psychotic episodes following ayahuasca or DMT use are rare but have been documented in both ritual and recreational/non‑controlled settings. Most reported cases involved a personal or family history of psychosis, bipolar/manic disorders or concomitant substance use, supporting psychiatric screening before administration and avoidance of hallucinogens in those with such histories.

Published: February 23, 2017
Journal: Therapeutic Advances in Psychopharmacology
Authors: Bouso, J. C., Dos Santos, R. G., Hallak, J. E.

Open Accessindividual

Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively

This placebo-controlled, double-blind, cross-over, within-subjects study (n=18) investigated whether ayahuasca (42 & 59.5mg/70kg DMT) impairs the ability to filter out unnecessary sensory information in healthy volunteers. This yielded mixed results, with evidence to support that ayahuasca impairs sensorimotor gating in the domain of auditory suppression, but not within the domain of visual-induced prepulse inhibition of the startle reflex.

Published: December 1, 2002
Journal: Psychopharmacology
Authors: Barbanoj, M. J., Riba, J., Rodríguez-Fornells, A.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ayahuasca and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ayahuasca papers Search all Schizophrenia trials Full Ayahuasca profile Full Schizophrenia profile